Samsung Semiconductor Europe Completes EMEA Headquarters Relocation to New Munich Office
18.11.2020 12:00:00 EET | Business Wire | Press release
Samsung Semiconductor Europe, a wholly owned subsidiary of Samsung Electronics. Co., Ltd. has announced today that the relocation of its EMEA headquarters from the Frankfurt region to Munich, a leading high-tech hub in Germany, is now completed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005044/en/
Samsung Semiconductor Europe at Bavaria Towers, Munich (Photo: Business Wire)
Aiming to be on the doorstep of many key customers and partners with whom the company is driving digital transformation across industries, Samsung Semiconductor Europe started moving into the new Bavaria Towers in early 2020. Consolidating the already existing Ismaning office along the way, the relocation process was finally completed by closing the previous location near Frankfurt by end of September.
“Faster response times to our customers and attracting the best talent in this technology hub are key for Samsung Semiconductor Europe to remain a leading solution provider for the next few decades,” said Dermot Ryan, managing director at Samsung Semiconductor Europe. “By embracing future trends like artificial intelligence (AI), 5G, internet of things (IoT), big data, cloud computing, automotive and more, we work at the chip and basic software level, not only to make our own devices more intelligent, but also to enable entire industries to become smarter. The move to Munich marks a new era for Samsung Semiconductor Europe as we embark upon a new age of innovation, cooperation and trust together with our employees, customers and partners.”
“As the state capital of Bavaria, Munich is not only an international and culturally diverse city in a beautiful environment, it is also Germany‘s foremost tech hub and one of the leading cities in digital transformation,“ says Clemens Baumgärtner, head of the Department of Labor and Economic Development, City of Munich. “Munich offers excellent infrastructure and a vibrant ecosystem of companies, universities, start-ups and professional networks to companies in the areas of high-tech, IoT and services. We are more than happy to welcome Samsung Semiconductor Europe to shape the future of our region together.”
Munich has not only a leading position within Germany’s ICT sector, with 119.000 employees and 11.300 companies in and around the area according to the Bavarian Statistical Office, it also ranks high within European ICT poles of excellence, according to a study of the European Commission.
At Bavaria Towers, Samsung Semiconductor Europe employs around 170 staff from a large variety of countries in sales and marketing for Samsung Electronics’ component business units in Europe, the Middle East and Africa along with its sales offices in Finland, France, Turkey and the UK. From a technology point of view, Samsung Semiconductor Europe provides component solutions featuring industry-leading technologies in the areas of memory, system LSI, foundry, LED and display, often setting a new standard in the industry.
The company also offers a dynamic work culture in an exciting and inspiring atmosphere. As employees’ health and safety are one of its top priorities, the company provides a variety of employee benefits for improved work-life balance and thrives on a diverse and empowering work environment.
To learn more about Samsung Semiconductor Europe, please visit https://www.linkedin.com/showcase/samsung-semi-europe/
###
About Samsung Semiconductor Europe GmbH
Samsung Semiconductor Europe, a wholly owned subsidiary of Samsung Electronics Co. Ltd., is headquartered in Munich, Germany and operates offices in Europe, Middle East and Africa (EMEA). Samsung Semiconductor's European base handles the marketing and sales of Samsung Electronics' component business units including Memory, System LSI, Foundry, LED and Display in EMEA for various applications including servers, data centres, mobile, industrial/automotive, IoT and more. For more information, please visit www.samsung.com/semiconductor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005044/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: ujeong.j@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 16:22:00 EEST | Press release
AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany,
JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 16:00:00 EEST | Press release
The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support the Olympic Movement and sport around the world. JPMorganChase’s global reach and expertise will
BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 16:00:00 EEST | Press release
BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin ® Delivery System for Overactive Bladder28.4.2026 15:42:00 EEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 15:28:00 EEST | Press release
CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom